Updated on 13 September 2012
Teva hopes to increase focus on Asia Pacific with the appointment of Professor Itzhak Krinsky
Singapore: Teva Pharmaceutical has appointed Professor Itzhak Krinsky as chairman of Teva Japan and Teva South Korea and head of Business Development Asia-Pacific. Currently serving as executive vice president, Corporate Business Development at Teva, Professor Krinsky's new appointment will be effective mid-October.
Professor Krinsky will be responsible for overseeing Teva's generic and branded pharmaceuticals businesses in Japan and South Korea. Additionally, Professor Krinsky will manage business development for the Asia-Pacific region. He will continue to serve as a member of the Teva executive committee and will be located in Tokyo, Japan.
Professor Krinsky will replace Mr Moshe Manor, president and chief executive officer of Teva Asia- Pacific who decided to retire from Teva. Professor Krinsky will report directly to Dr Jeremy Levin, president and CEO of Teva Pharmaceutical Industries. Professor Krinsky's former responsibilities as head of business development will become a part of the office of the CEO and remain a key focus for Teva.
"As part of our global strategic plan and in response to our growing presence in Asia-Pacific, we are positioning this part of our business to focus on the strong growth prospects in this region," said Dr Levin. "We are committed to aggressively competing in these markets and the appointment of Professor Krinsky along with our dedicated and talented teams already in place allows us to more closely manage these geographies as we deliver even more value to patients around the world. In addition, Prof Krinsky's extensive experience in business development will be invaluable in assisting our regional leaders in Asia-Pacific in their business development efforts which will focus on potential opportunities that complement our strategy in these key emerging markets."
"It is a privilege and a pleasure for me to be a part of these vibrant and dedicated regional teams," said Prof Krinsky. "In addition, I am looking forward to continuing to support Teva's business development efforts by working closely with the regional leaders in Asia as we leverage our expertise to maximize the potential of our businesses in Asia-Pacific."